{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T08:11:43Z","timestamp":1772525503588,"version":"3.50.1"},"reference-count":14,"publisher":"Japanese Society of Internal Medicine","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,9,15]]},"DOI":"10.2169\/internalmedicine.5347-20","type":"journal-article","created":{"date-parts":[[2021,4,4]],"date-time":"2021-04-04T22:06:30Z","timestamp":1617573990000},"page":"2973-2977","source":"Crossref","is-referenced-by-count":4,"title":["Symptomatic Sinus Bradycardia in a Patient with Solitary Fibrous Tumor\/Hemangiopericytoma Treated with Pazopanib"],"prefix":"10.2169","volume":"60","author":[{"given":"Wataru","family":"Shioyama","sequence":"first","affiliation":[{"name":"Department of Onco-Cardiology, Osaka International Cancer Institute, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Oka","sequence":"additional","affiliation":[{"name":"Department of Onco-Cardiology, Osaka International Cancer Institute, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Risa","family":"Kamada","sequence":"additional","affiliation":[{"name":"Department of Onco-Cardiology, Osaka International Cancer Institute, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshinari","family":"Yagi","sequence":"additional","affiliation":[{"name":"Department of Cancer Chemotherapy Center for Outpatients, Osaka International Cancer Institute, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiko","family":"Nakanishi","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Osaka International Cancer Institute, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Department of Onco-Cardiology, Osaka International Cancer Institute, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Yasui","sequence":"additional","affiliation":[{"name":"Department of Onco-Cardiology, Osaka International Cancer Institute, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Onco-Cardiology, Osaka International Cancer Institute, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Hamberg P, Verweij J, Sleijfer S.  (Pre-) clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist 15: 539-547, 2010.","DOI":"10.1634\/theoncologist.2009-0274"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379: 1879-1886, 2012.","DOI":"10.1016\/S0140-6736(12)60651-5"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Justice CN, Derbala MH, Baich TM, et al. The impact of pazopanib on the cardiovascular system. J Cardiovasc Pharmacol Ther 23: 387-398, 2018.","DOI":"10.1177\/1074248418769612"},{"key":"4","unstructured":"4. US National Cancer Institute. Common Terminology Criteria for Adverse Events, version 5.0 [Internet]. 2017 Nov 27 [cited 2021 Jul 16]. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Stout AP, Murray MR. Hemangiopericytoma: a vascular tumor featuring Zimmermann's pericytes. Ann Surg 116: 26-33, 1942.","DOI":"10.1097\/00000658-194207000-00004"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131: 803-820, 2016.","DOI":"10.1007\/s00401-016-1545-1"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Lee SJ, Kim ST, Park SH, et al. Successful use of pazopanib for treatment of refractory metastatic hemangiopericytoma. Clin Sarcoma Res 4: 13, 2014.","DOI":"10.1186\/2045-3329-4-13"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Park MS, Patel SR, Ludwig JA, et al. Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer 117: 4939-4947, 2011.","DOI":"10.1002\/cncr.26098"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kasper B, Sleijfer S, Liti\u00e8re S, et al. Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072. Ann Oncol 25: 719-724, 2014.","DOI":"10.1093\/annonc\/mdt586"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 27: 3126-3132, 2009.","DOI":"10.1200\/JCO.2008.21.3223"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Takada M, Yasui T, Oka T, et al. Aortic dissection and cardiac dysfunction emerged coincidentally during the long-term treatment with angiogenesis inhibitors for metastatic renal cell carcinoma. Int Heart J 59: 1174-1179, 2018.","DOI":"10.1536\/ihj.17-461"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Nazer B, Humphreys BD, Moslehi J. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Circulation 124: 1687-1691, 2011.","DOI":"10.1161\/CIRCULATIONAHA.110.992230"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Werner-Wasik M, Rudoler S, Preston PE, et al. Immediate side effects of stereotactic radiotherapy and radiosurgery. Int J Radiat Oncol Biol Phys 43: 299-304, 1999.","DOI":"10.1016\/S0360-3016(98)00410-6"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Ou SH, Tang Y, Polli A, Wilner KD, Schnell P. Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large-scale multinational trials (PROFILE 1005 and 1007). Cancer Med 5: 617-622, 2016.","DOI":"10.1002\/cam4.622"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/18\/60_5347-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T03:14:15Z","timestamp":1631934855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/18\/60_5347-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,15]]},"references-count":14,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5347-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,15]]},"article-number":"5347-20"}}